STOCK TITAN

ImmunityBio, Inc. - $IBRX STOCK NEWS

Welcome to our dedicated page for ImmunityBio news (Ticker: $IBRX), a resource for investors and traders seeking the latest updates and insights on ImmunityBio stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ImmunityBio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ImmunityBio's position in the market.

Rhea-AI Summary

ImmunityBio (NASDAQ: IBRX) announced three podcasts with UroToday discussing the FDA approval of ANKTIVA® (N-803) plus BCG for non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS). Dr. Patrick Soon-Shiong and Dr. Ashish Kamat highlighted ANKTIVA’s unique mechanism, which activates NK cells, killer T cells, and memory T cells to fight tumors. They emphasized the collaboration with Serum Institute of India to address BCG shortages. ANKTIVA, an IL-15 receptor agonist, offers a new treatment option for BCG-unresponsive NMIBC patients, promoting durable complete responses by converting MHC-negative tumors to MHC-positive. The podcasts are available on UroToday's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
none
-
Rhea-AI Summary

ImmunityBio, Inc. (NASDAQ: IBRX) has completed the drug substance manufacturing for ANKTIVA, providing 170,000 doses, with two-year storage stability data. The company's GMP fill-finish facility in New York is on track for completion in 12-18 months, capable of producing a million vials annually. The recent partnership with the Serum Institute of India for BCG availability enhances the company's inventory and capacity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.76%
Tags
none
-
Rhea-AI Summary

ImmunityBio, Inc. (NASDAQ: IBRX) has entered into an exclusive global agreement with the Serum Institute of India to supply Bacillus Calmette-Guerin (BCG) for use in combination with ImmunityBio's ANKTIVA.

This collaboration will address the chronic BCG supply shortage issue, providing both standard BCG (sBCG) and next-generation recombinant BCG (iBCG) for approved indications benefiting from ANKTIVA's therapeutic effects.

The agreement aims to enhance immunogenicity and safety compared to standard BCG, improving outcomes for bladder cancer patients globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
none
Rhea-AI Summary

ImmunityBio's Executive Chairman, Dr. Patrick Soon-Shiong, will discuss the recent FDA approval of ANKTIVA® for use in combination with BCG for non-muscle invasive bladder cancer at the AUA 2024 conference. ANKTIVA's Breakthrough Therapy designation and novel mechanism will be highlighted, offering an alternative therapy to radical surgery for advanced bladder cancer cases. The discussion will focus on transforming cold bladder cancer cells to hot tumors via ANKTIVA's activation of NK and T cells, resulting in durable responses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.12%
Tags
none
-
Rhea-AI Summary
ImmunityBio, Inc. (NASDAQ: IBRX) announces positive overall survival results in the QUILT 3.055 trial for non-small cell lung cancer patients who did not respond to checkpoint inhibitors. The study showed a nearly double median overall survival compared to standard chemotherapy. ANKTIVA, an immune cell enhancer, displayed efficacy in PD-L1 negative and positive patients, activating natural killer cells and memory T cells. A meeting with the FDA is scheduled to discuss registration for ANKTIVA in combination with checkpoint inhibitors. The company received a $100 million non-dilutive cash infusion, bringing cash-on-hand to $240 million for the launch of ANKTIVA in bladder cancer. ImmunityBio plans to discuss registration plans and clinical trial pipeline during a conference call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.02%
Tags
none
-
Rhea-AI Summary
ImmunityBio's ANKTIVA, a first-in-class IL-15 receptor agonist, receives FDA approval as a breakthrough therapy for BCG-unresponsive non-muscle invasive bladder cancer. The therapy activates the body's immune system to target tumor cells, leading to long-lasting complete responses. ANKTIVA in combination with BCG shows durable responses exceeding 47 months, exceeding clinical benchmarks. Availability in the U.S. is expected by mid-May 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.13%
Tags
Rhea-AI Summary
ImmunityBio (IBRX) announces promising preclinical data on N-803 and broadly neutralizing antibodies for HIV treatment. Clinical trials underway to test viral load reduction in HIV-infected individuals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.39%
Tags
none
-
Rhea-AI Summary
ImmunityBio (NASDAQ: IBRX) announces positive results from a Phase 1 pilot study showing N-803 combined with natural killer cells may reduce viral load in HIV patients. All participants experienced a significant decrease in infection levels. The approach was safe and well-tolerated, paving the way for further research in HIV cure-related clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.93%
Tags
none
-
Rhea-AI Summary
ImmunityBio (IBRX) announces enrollment in a national trial testing Nant Cancer Vaccine for Lynch syndrome individuals to prevent colon and other cancers. The study includes a tri-valent Adenovirus and IL-15 superagonist N-803 to activate immune cells. Lynch syndrome patients are at high risk for various cancers. The trial aims to prevent cancer by targeting cancer-specific proteins and enhancing immune response. Enrollment for the safety portions of the trial is completed, with a total of 186 participants expected.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
none
Rhea-AI Summary
ImmunityBio, Inc. (IBRX) announces positive Patient-Reported Outcomes (PROs) from the QUILT 3.032 trial of N-803 plus BCG for non-muscle invasive bladder cancer. The PROs indicate stability of physical function and global health in patients who completed questionnaires and reached month 24 on-study, supporting the safety and tolerability of the potential new treatment combination. The FDA is reviewing the Biologics License Application (BLA) for N-803 plus BCG, with a PDUFA date of April 23, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
none
ImmunityBio, Inc.

Nasdaq:IBRX

IBRX Rankings

IBRX Stock Data

4.51B
145.27M
79.62%
8.85%
8.09%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
SAN DIEGO

About IBRX

immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer (‘nk’) and t cells, tumoricidal macrophages, and memory t cells.